Huahai Pharmaceutical Industry: Mesalazine Enteric-coated Tablets Granted Drug Registration Certificate.

Huahai Pharmaceuticals announced that the company has recently received the "Drug Registration Certificate" for the approval and issuance of Mesalazine Enteric-coated Tablets from the National Medical Products Administration. The drug specification is 0.5g and it is mainly used for the treatment of ulcerative colitis and Crohn's disease. According to data from MiNeT, the domestic market size of this product is estimated to be around 787 million yuan by 2025. Up to now, the company has invested approximately 12.43 million yuan in research and development expenses for this project. This approval is expected to be equivalent to passing a consistency evaluation, which will help to enrich the company's product line and enhance market competitiveness.